Clinical Trials Logo

Clinical Trial Summary

This is a Phase I/IIa open, uncontrolled, prospective study, to be conducted in an out-patient setting. The present study is one of two clinical trials of the RNActive®-derived vaccine CV9103 being conducted concurrently in the US and Europe, which represent the first clinical trials conducted for this novel vaccine.

The Phase I part of the study consists of a staggered inclusion of subjects in two cohorts of 3, to confirm the safety of the intended dose (320 µg RNA per antigen), with a lower dose to be considered in case of dose-limiting toxicity (DLT) being reported in greater than or equal to 2 out of 3-6 subjects; in this way, the recommended dose (RD) for the Phase IIa part of the study will be established. In the Phase IIa part of the study, additional subjects will be included at the RD, to confirm the safety and explore the activity of that dose.


Clinical Trial Description

Medical Need:

At present, no curative therapy is available for subjects with advanced or metastatic prostate cancer. Approximately 1 of every 3 men present with advanced or metastatic disease; therefore, current standard therapies are ineffective and new therapeutic approaches are warranted. There is ample evidence that active immunotherapy against cancer is safe and capable of stimulating potentially therapeutic immune responses in the cancer patient. Moreover, several Phase II immunotherapy trials have suggested clinical benefit by reducing the tumor mass or prolonging time to progression in subjects with advanced prostate cancer.

Potential Benefits:

CV9103 is an mRNA-based vaccine for the treatment of human prostate cancer that is based on CureVac's RNActive® technology. CV9103 encodes for 4 prostate specific antigens. Because these antigens are present in prostate cancer cells, they are appropriate targets for intervention. These antigens have been shown to correlate frequently with the progression of prostate cancer, and are known to be immunogenic in humans, where they induce antigen specific T-cell or B cell expansion.

As an RNA-based vaccine, CV9103 features several advantages over other approaches: it is highly specific, there is no restriction to the patient's MHC genotype, and it does not need to cross the nuclear membrane to be active. Finally, in the absence of reverse transcriptase, RNA can not be integrated into the genome.

CV9103 will be administered in 5 doses. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00906243
Study type Interventional
Source University of Florida
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date May 2009
Completion date December 2010

See also
  Status Clinical Trial Phase
Completed NCT00069745 - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen Phase 3
Completed NCT01260688 - Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel Phase 2
Completed NCT00571675 - A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) Phase 2
Withdrawn NCT02867345 - PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
Completed NCT01741116 - Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer Phase 2
Recruiting NCT00795171 - Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer Phase 2
Terminated NCT00525408 - A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer Phase 2
Completed NCT00667199 - BAY88-8223, Does Response Study in HRPC Patients Phase 2
Recruiting NCT02955082 - The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment Phase 2
Recruiting NCT01590498 - Radiotherapy vs Observation for CRPC N/A
Completed NCT01518283 - Study of Weekly Cabazitaxel for Advanced Prostate Cancer Phase 2
Terminated NCT00493766 - Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone Phase 1
Terminated NCT01083615 - A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Phase 3
Completed NCT00987753 - Study Evaluating the Safety and Tolerability of L-377202 Phase 1/Phase 2
Recruiting NCT02208583 - Molecular Phenotype Changes and Personalized Treatment for CRPC N/A
Completed NCT00928252 - Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer Phase 1/Phase 2
Completed NCT00699751 - A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases Phase 3
Recruiting NCT00411853 - Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients Phase 2
Active, not recruiting NCT00448734 - A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer Phase 1/Phase 2
Completed NCT00510718 - A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer Phase 1